Pharmacogenetics

Blog Archives

Clinical evidence and implementation challenges for pharmacogenomic testing

Posted on September 18, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Personomics, Pharmacogenetics, Thasso Post, Theragenomic Medicine No Comments ↓

September 18, 2019 – This post is an edited version of parts of a paper that appeared in the Journal of Personalised Medicine (JPM) a week ago und which addresses one of the important topics in connection with the themes of personalised medicine,

…

Tags: All of Us Project, Canadian Association of Genetic Counsellors, Clinical Pharmacogenetics Implementation Consortium (CPIC), Direct To Consumer Genetic Testing (DTCGT), Dutch Pharmacogenetics Working Group (DPWG), Genetic Testing, Next Generation Sequencing (NGS), Pharmacogenomics, PharmGKB, PREDICT Program, Right Dose, Right Drug, Right Time Protocol (RIGHT Protocol), Thasso Post, Theragenomic Medicine, Ubiquitous Pharmacogenomics Project (UPGX), US National Society of Genetic Counselors

Genomics lab illegally markets genetic tests that claim to predict patient responses to drugs

Posted on April 7, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Pharmacogenetics, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process of understanding what, if any, role genetics plays in a patient’s reaction to particular drugs,

…

Tags: American Food & Drug Administration (FDA), Direct To Consumer Genetic Testing (DTCGT), Direct To Consumer Theragenomic Testing (DTCTT), Inova Genomics Laboratory, MediMap ADHD, MediMap BabyToday, MediMap Heart, MediMap Mind, MediMap Plus

Direct Oral Anticoagulants (DOAC): Newly Identified Genes and Genetic Variants

Posted on January 26, 2019 by by

thassodotcom Posted in Drug/Drug Interaction, Genetic Background, New Research, Pharmacogenetics, Thasso Post, Theragenomic Medicine No Comments ↓

January 26, 2019 – Pharmacogenomic approaches are increasingly revealing newly identified genes and genetic variants that are at the base of remarkable inter-individual pharmacokinetic and pharmacodynamic variation of novel direct oral anticoagulants (DOAC).

…

Tags: ABCB1 Gene, Apixaban (Eliquis), CES1 Gene, CYP2C9 Gene, CYP3A4 Gene, Dabigatran [Pradaxa], Direct Oral Anticoagulants (DOAC), Drug-Drug Interaction, Edoxaban (Savaysa), Factor Xa Gene, Genetic Locus, Genetic Variants, Idarucizumab (Praxbind), P-glycoprotein, Rivaroxaban (Xarelto), Single-Nucleotide Polymorphism (SNP), SLCOB1 Gene, Thasso Post, Theragenomic Medicine, VKORC1 Gene

Living theragenomic medicine: Direct to consumer test for metabolism of drugs FDA approved

Posted on November 8, 2018 by by

thassodotcom Posted in Genetic Background, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 08, 2018 – The American Food and Drug Administration (FDA) has just authorized the first direct-to-consumer test for detecting genetic variants in genes that may govern the metabolism of drugs in individual patients.

Thus, FDA permits marketing, with special controls,

…

Tags: 23andMe, 23andMe Personal Genome Service Pharmacogenetic Report, Allelic Variant, American Food & Drug Administration (FDA), Canadian Pharmacogenomics Network for Drug Safety (CPNDS), Clinical Pharmacogenetics Implementation Consortium (CPIC), Direct To Consumer Genetic Testing, European Medicines Agency (EMA), Flockhart Table, Genetic Variant, Health Canada (HCSC), Japan (PMDA), Pharmaceuticals and Medical Devices Agency, PharmKGB, Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group (DPWG), Thasso Post, Theragenomic Medicine

Development of a patient education video about pharmacogenetics

Posted on June 16, 2017 by by

thassodotcom Posted in Companion Test, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Pharmacogenetics, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

June 16, 2017 – Patient education in pharmacogenetics, the central component of theragenomic and personalized medicine and individualized drug safety is an important issue. Not only needs the individual patient to understand what pharmacogenetics, or more precisely, pharmacogenetic testing can do for him in the process of

selection of the “right”

…

Tags: Patient Education Video, Patient Subgroups, Pharmacogenetics, Precision Medicine, Thasso Post, Theragenomic Medicine

Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved

Posted on September 20, 2016 by by

thassodotcom Posted in Genetic Background, In The Press, New Drug Approval, Personalized Medicine, Pharmacogenetics, Rare Diseases, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy option which gives much hope for at least some of the affected patients.

…

Tags: American Food & Drug Administration (FDA), Duchenne Muscular Dystrophy (DMD), Dystrophin Gene, Eteplirsen (Exondys 51), Exon 51, Mutation, Targeted Therapy, Thasso Post, Theragenomic Medicine

Actionable pharmacogenetic markers for prediction and prognosis in breast cancer

Posted on August 22, 2016 by by

Sacco K, Grech G Posted in Personalized Medicine, Pharmacogenetics, PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

Sacco K, Grech G

EPMA J 2015;6(1):15

PMID: 26203310

Abstract

Breast cancer is a heterogeneous disease that necessitates proper patient classification to direct surgery, pharmacotherapy, and radiotherapy. Despite patients within the same subgroup receiving similar pharmacotherapy, substantial variation in clinical outcomes is observed.

…

Tags: Allelic Variant, Biomarkers, Breast Cancer, Clinical Outcome, Genotype, Pharmacogenetic Variants, Pharmacotherapy, Phenotype, Predictive Biomarkers, Prognostic Biomarker, Tamoxifen, Thasso Post, Theragenomic Medicine, Trastuzumab [Herceptin]

Precision Medicine Initiative: draft guidances issued

Posted on July 11, 2016 by by

thassodotcom Posted in Allelic Variant, Companion Test, Diagnostic, Genetic Background, Genetic Predisposition, Genetic Susceptibility, On The Horizon, Personalized Medicine, Pharmacogenetics, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

July 9, 2016 – This is a huge step into the future of theragenomic and personalized medicine and individualized drug safety. In support of the President’s Precision Medicine Initiative (PMI), the American Food & Drug Administration (FDA) just issued two draft guidances that,

…

Tags: Draft Guidance, Individualized Drug Safety, Next Generation Sequencing (NGS), Personalized Medicine, Precision Medicine, Precision Medicine Initiative, Thasso Post, Theragenomic Medicine

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

Posted on February 7, 2016 by by

thassodotcom Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized No Comments ↓

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

…

Tags: American Food & Drug Administration (FDA), EGFR T790M Mutation, Epidermal Growth Factor Receptor (EGFR), European Medicine Agency (EMA), Non-Small Cell Lung Cancer (NSCLC), Osimertinib (Tagrissa), Patient Subgroup, Tyrosine-Kinase Inhibitor (TKI)

Genetic Variants Predict Lithium Response in Bipolar Disorder

Posted on February 4, 2016 by by

thassodotcom Posted in Allelic Variant, On The Horizon, Personalized Medicine, Pharmacogenetics, Targeted Therapy, Thasso Post No Comments ↓

February 04, 2016 – Genetic variations on a stretch of chromosome may predict responsiveness among patients with bipolar disorder to the mood stabilizing drug lithium (multiple brands), a genome-wide analysis by an international consortium shows.

…